Terence Kelly

Terence Kelly

Company: Perception Neuroscience

Job title: CEO

Seminars:

1PCN-101 (R-ketamine) for Treatment Resistance Depression 10:25 am

• PCN-101 is being developed by Perception Neuroscience for TRD and other mood disorders • A Phase 1 SAD study in HV was completed which demonstrated good tolerability and safety • Thoughts on the potential for a wider therapeutic window will be discussed.Read more

day: Day One

Live Q&A 10:50 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.